MondayMay 22, 2023 12:40 pm

TinyGemsBreaks – Cepton Inc. (NASDAQ: CPTN) Overcoming Primary Barriers to Commercialization of Lidar for ADAS

Cepton (NASDAQ: CPTN) is commercializing lidar systems for autonomous vehicles and advanced driver-assistance systems (“ADAS”) as well as developing solutions for a range of other industries. “Commercialization of lidar for ADAS faces two primary obstacles: perception capabilities and sensor embeddability into modern vehicle designs. Lidar pioneer Cepton’s Ultra-Slim Vista(R) Plus lidar overcomes both barriers while setting new industry standards. Billed by CPTN as the ‘world’s smallest’ adaptive long-range lidar, the Vista-X90 Plus is 62% slimmer than its predecessor – the Vista(R)-X90 – with a 58% footprint reduction. Besides offering an extremely streamlined solution for windshield integration, the Vista-X90 Plus can…

Continue Reading

FridayApr 21, 2023 1:46 pm

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advancing Potentially Pivotal Berubicin Trial

CNS Pharmaceuticals (NASDAQ: CNSP) recently reported the enrollment of the first patient in Switzerland as a participant in its ongoing potentially pivotal global trial evaluating Berubicin for the treatment of glioblastoma multiforme (“GBM”). “CNS Pharmaceutical’s adaptive, multicenter, open-label, randomized controlled study targets adult patients with recurrent GBM after failure of standard first-line therapy. In addition, the study will also enroll patients who have received additional treatments as part of the first-line therapy in recognition of the complexity of new agents introduced as a component of this therapy. The study will compare Berubicin, a novel anthracycline and the first anthracycline to…

Continue Reading

FridayApr 21, 2023 12:45 pm

TinyGemsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Differentiated with Focus on Tech-Driven Solutions, Outstanding Customer Service

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”) recently acknowledged an endorsement by leading investment and research firm Chardan Capital Research that included a buy rating for the company at a price target of $2.00. “We are pleased to be able to share the results of Chardan’s independent analysis of our company’s growth and potential. Our focus on technology-driven solutions and outstanding customer service has allowed us to differentiate ourselves in the market, and we will continue to build on that success,” a recent article quotes Fr8Tech CEO Javier Selgas as saying. “Fr8Tech has built a suite of technology-based solutions to help automate…

Continue Reading

FridayApr 14, 2023 12:52 pm

TinyGemsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Demonstrates Positive Results in First Diabetes Study

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, is increasing the bioavailability of and improving the way that active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery with its patented DehydraTECH(TM). “Most recently, a company announcement indicates that a just-completed DIAB-A22-1 diabetes study has produced at least three positive outcomes, including weight loss in obese diabetic-conditioned animals and improved triglyceride and cholesterol levels. The animals tested in the study showed these dramatic changes in as few as three days when dosed with DehydraTECH-processed cannabidiol (‘CBD’), aligned with other study work pointing to…

Continue Reading

FridayMar 24, 2023 12:33 pm

TinyGemsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Efforts to Boost Commercial Prospects ‘Paying off in Spades’

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator developing and commercializing its patented DehydraTECH(TM) drug delivery technology. Lexaria is continuing and/or initiating discussions with several larger companies in Europe and North America regarding the licensed use of its technology for both consumer and pharmaceutical sectors. “The materialization of such partnerships hinges on a number of must-haves. Firstly, there must be a tangible product that draws larger companies. Secondly, The decision of whether or not to invest, and the scale of any investment, is based on how well the technologies that form the core of a company have been protected.…

Continue Reading

WednesdayMar 22, 2023 11:00 am

TinyGemsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Eyes Continued Growth in Cross-Border and Domestic FTL Offerings

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), an over-the-road shipping technology innovator, is dedicated to keeping freight moving around the country and between the United States’ primary land-based trading partners in an efficiently designed and successful manner. The company does this using its flagship AI-powered Fr8App B2B marketplace as a powerful tool. “Fr8Tech recently announced its market guidance data, projecting revenues of between $36 million and $42 million for 2023, which will be an increase over 2022’s preliminary revenue figures of approximately $26 million to $27 million. The company’s projections for revenue growth are underscored by the comments President Biden made during…

Continue Reading

FridayMar 17, 2023 1:28 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Moving Closer to Providing Alternative Hypertension Treatment with DehydraTECH(TM)-CBD

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently reported additional findings from its most comprehensive clinical study yet, HYPER-H21-4. “The findings showed that DehydraTECH-CBD resulted in a statistically significant reduction in average baseline serum catestatin concentrations of 13.50 ng/mL to just 9.65 ng/mL after five weeks of dosing, representing a 28.5% drop. In addition, mean arterial pressure significantly dropped by 4.26 ± 1.26 mm/Hg following the five weeks of DehydraTECH-CBD dosing. No statistically significant reductions in catestatin concentrations were identified in the placebo group,” a recent article reads. “Given the growing demand for alternative anti-hypertensive…

Continue Reading

WednesdayMar 08, 2023 3:13 pm

TinyGemsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Improves Product Performance Across Multiple Categories

Lexaria (NASDAQ: LEXX) is a global innovator in drug delivery platforms. “The company’s patented DehydraTECH(TM) technology enhances the performance of multiple categories of fat-soluble active molecules and drugs available in various formats, including oral ingestible, oral buccal/sublingual and topical products. According to Lexaria, its technology ‘is best thought of as an additional layer that improves the effectiveness of existing or planned new products for companies that offer consumer supplements, prescription and non-prescription-based drugs and nicotine products,’” a recent article reads. “When analyzed in terms of numbers, the improvements are impressive. Having conducted both in vitro and in vivo studies, Lexaria…

Continue Reading

FridayMar 03, 2023 2:45 pm

TinyGemsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Modernizing Operations for Shippers and Carriers in USMCA Region

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a North American transportation logistics technology company, understands the direct relationship between successful, efficient trade and logistics services. “Through its in-house technologies, which are powered by artificial intelligence (‘AI’), Fr8Tech seeks to modernize operations for shippers and carriers in Mexico, Canada and the U.S. [the USMCA region] by optimizing logistics, reducing transportation costs and making fleets more efficient. All these benefits are anchored in an innovative digital freight matching technology: the Fr8App B2B marketplace. Fr8App is a central, cloud-based control center that connects shippers and carriers, matching them based on the former’s unique shipping needs…

Continue Reading

FridayFeb 17, 2023 12:55 pm

TinyGemsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD Demonstrates ~1,900% Better Permeability Through Skin

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced its 28th granted patent worldwide and the first granted patent from its sixth patent family, titled Transdermal And/or Dermal Delivery of Lipophilic Active Agents. “The Canadian patent #3,093,414 is for improved compositions and methods for transdermal and dermal delivery of cannabinoids, including cannabidiol (‘CBD’) and tetrahydrocannabinol (‘THC’), all established on the company’s patented DehydraTECH technology,” a recent article reads. “In Lexaria’s 2018 study, DehydraTECH-CBD demonstrated almost a 1,900% increase in CBD permeability through human skin compared to a control formulation that was devoid of any commercial…

Continue Reading

Contact us: (310) 299-1717